VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
0.1485
-0.0109 (-6.84%)
At close: Oct 23, 2026, 4:00 PM EDT
0.1500
+0.0015 (1.01%)
After-hours: Oct 23, 2026, 7:32 PM EDT
VivoSim Labs Employees
As of June 30, 2026, VivoSim Labs had 15 total employees, including 9 full-time and 6 part-time employees. The number of employees did not change since the number was last reported on March 31, 2026. That makes VivoSim Labs the 39,348th largest employer in the world and 5,773rd in the United States.
Employees
15
Change
n/a
Growth
n/a
Revenue / Employee
$7,467
Profits / Employee
-$822,533
Market Cap
2.46M
Employees Chart
| Date | Employees | Change | Growth | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 15 | 0 | - | 15 | 0 |
| Mar 31, 2026 | 15 | 2 | 15.38% | 9 | 6 |
| Mar 31, 2025 | 13 | -7 | -35.00% | 5 | 8 |
| Mar 31, 2024 | 20 | -4 | -16.67% | 12 | 8 |
| Mar 31, 2023 | 24 | 6 | 33.33% | 15 | 9 |
| Mar 31, 2022 | 18 | 9 | 100.00% | 9 | 9 |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| PMGC Holdings | 34 |
| Aptevo Therapeutics | 33 |
| Calidi Biotherapeutics | 29 |
| Lunai Bioworks | 12 |
| Revelation Biosciences | 9 |
| Eocene | 6 |
| Mustang Bio | 4 |
VIVS News
- 3 days ago - VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling - GlobeNewsWire
- 17 days ago - VivoSim celebrates updated FDA regulations in non-animal testing methods - TheFly
- 17 days ago - VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods - GlobeNewsWire
- 5 weeks ago - VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs - GlobeNewsWire
- 7 weeks ago - VivoSim Labs to Add Rat Liver Model to NAMkind Platform - GlobeNewsWire
- 2 months ago - VivoSim regains compliance with Nasdaq - TheFly
- 2 months ago - VivoSim Provides Financial and Listing Compliance Update - GlobeNewsWire
- 2 months ago - VivoSim files to sell 9.41M shares of common stock for holders - TheFly